- Home
- VABK vs YMAB Comparison
VABK vs YMAB Comparison
Compare VABK & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VABK
- YMAB
- Stock Information
- Founded
- VABK 1998
- YMAB 2015
- Country
- VABK United States
- YMAB United States
- Employees
- VABK N/A
- YMAB N/A
- Industry
- VABK Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- VABK Finance
- YMAB Health Care
- Exchange
- VABK Nasdaq
- YMAB Nasdaq
- Market Cap
- VABK 206.0M
- YMAB 218.4M
- IPO Year
- VABK N/A
- YMAB 2018
- Fundamental
- Price
- VABK $35.03
- YMAB $4.10
- Analyst Decision
- VABK
- YMAB Buy
- Analyst Count
- VABK 0
- YMAB 11
- Target Price
- VABK N/A
- YMAB $18.73
- AVG Volume (30 Days)
- VABK 5.2K
- YMAB 276.3K
- Earning Date
- VABK 04-24-2025
- YMAB 05-06-2025
- Dividend Yield
- VABK 3.75%
- YMAB N/A
- EPS Growth
- VABK 3.77
- YMAB N/A
- EPS
- VABK 3.30
- YMAB N/A
- Revenue
- VABK $54,740,000.00
- YMAB $87,685,000.00
- Revenue This Year
- VABK N/A
- YMAB N/A
- Revenue Next Year
- VABK N/A
- YMAB $21.10
- P/E Ratio
- VABK $10.73
- YMAB N/A
- Revenue Growth
- VABK 1.08
- YMAB 3.38
- 52 Week Low
- VABK $24.81
- YMAB $3.84
- 52 Week High
- VABK $44.00
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- VABK 51.08
- YMAB 40.35
- Support Level
- VABK $35.14
- YMAB $3.91
- Resistance Level
- VABK $36.79
- YMAB $4.93
- Average True Range (ATR)
- VABK 1.02
- YMAB 0.45
- MACD
- VABK 0.02
- YMAB -0.03
- Stochastic Oscillator
- VABK 40.86
- YMAB 16.25
About VABK Virginia National Bankshares Corporation
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses and charitable organizations.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.